Name: Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo (en Inglés)
Price: 99550.00 CLP
Availability: InStock
Author: Danziger, Robert S. ; Scott, John T.
ISBN: 9781680838206

portada Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo (en Inglés)

Formato

Libro Físico

Autor

John T. Scott

Robert S. Danziger

Editorial

Now Publishers

Idioma

Inglés

N° páginas

114

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 0.6 cm

Peso

0.17 kg.

ISBN13

9781680838206

Categorías

Economía política
Tecnología: cuestiones generales

Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo (en Inglés)

John T. Scott (Autor) · Robert S. Danziger (Autor) · Now Publishers · Tapa Blanda

Libro Físico

$ 99.550

$ 165.910

Ahorras: $ 66.360

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 29 de Mayo y el Lunes 10 de Junio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding: Illustrated with the Technolo (en Inglés)"

This study develops a detailed description of the successful technology transfer of an invention - the drug-eluting coronary stent - originating in intramural research within the US National Institutes of Health. The history of the commercialization of the invention is used to illustrate a new policy, proposed and explained in this study, for the payment to the government of royalties on the sales of biomedical products developed with substantial public funding provided through indirect as well as direct funding avenues. The proposed policy addresses concerns about the high prices that taxpayers as consumers pay for biomedical products that were developed with funding from the taxpayers as investors. The study explains the theoretical circumstances in which the policy would not adversely affect the appropriate level of R&D investment, and then uses the history of the drug-eluting coronary stent as an example where biomedical R&D is consistent with those circumstances.